dr. Merce Boada, dr. med., nevrologinja
Member of the Executive Committee of the European Alzheimer’s Disease Consortium (EADC) and founder member of the Mediterranean Alzheimer Alliance (MAA).
Leader of several projects funded by Spanish, Catalan, European Union and private institutions: AES, H2020 , EFSD, ERA-NET, IMI2, Fundació La Caixa.
To date, she has led 128 clinical trials as well as being author of more than 150 articles, 25 book chapters and 12 books of medical outreach.
Among other awards, Mercè Boada has received the Professional Excellence Award by the Medical Council of Catalonia (2008); the Josep Trueta Medal for Health Merit, from the Generalitat de Catalunya (2012) and, the highest honor conferred by the Catalan Government, the “Creu de Sant Jordi”
(St. George’s Cross) for her work in the field of Alzheimer’s disease.
Is MCI predictor of AD?
The clinical evolution of Alzheimer’s disease (AD) is well‐founded in a subtle and progressive loss
of cognitive functions, in which the memory chairs the symptomatic courtship. Even today the
AD can be defined as a losing process, from the benign forgetfulness himself.
Alzheimer’s disease research is at a critical time. The global society is increasingly aware of the
frightening rate of growth of the human and financial burden caused by this condition, and of
the urgent need to halt its progression. In the wake of this increased sense of urgency, society
is calling for increased action and governments worldwide are responding by recognizing
dementia as a public health priority and increase funding and define strategies to defeat AD.
Today, a rapidly growing number of individuals with mild cognitive impairment (MCI) specifically
ask for biomarker‐based prediction of AD. Consequently the scientific community holds great
responsibility to quickly put in place and optimize the machinery necessary for testing new
treatments or interventions. In clinical practice, specialist increasingly offers predictive diagnosis
to patients. However, the expectations and attitudes of patients and their caregivers are yet
For its success, it is necessary that researchers establishing contact understand the culture of
the community and maintain direct and stable contact. The concept of community based
participatory research (CBPR) defines a structured and bidirectional methodology of community
outreach that endeavors to reduce the distance between researchers and a community by
establishing a forum of mutual communication and learning. Investigators inform of research
results with the objective of causing a positive impact in the health of the community and so its
members understand the importance of scientific research and the principles it is based on.
Social, clinic and basic research in AD is moving forward to detect hidden individuals at the
earliest stages of the disease and, why not, look for volunteers asymptomatic individuals to
understand cause and consequences of this complex polyhedral process.
The aim of this update is to learn about the specific attitudes and expectations towards
prediction and prevention of AD as well as future new topics for improve their quality of life.